Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial
| Autor: | Manish K. Jha, Bruce D. Grannemann, Taryn L. Mayes, Tracy L. Greer, Madhukar H. Trivedi, A. John Rush, Bharathi S. Gadad, Abu Minhajuddin, Abigail A. Soyombo |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male medicine.medical_specialty Endocrinology Diabetes and Metabolism Citalopram Article 03 medical and health sciences 0302 clinical medicine Endocrinology Internal medicine medicine Humans Psychiatry Bupropion Biological Psychiatry Depression (differential diagnoses) Selection (genetic algorithm) Depressive Disorder biology Endocrine and Autonomic Systems business.industry C-reactive protein Remission Induction Acute-phase protein Middle Aged Antidepressive Agents 030227 psychiatry Psychiatry and Mental health Antidepressant medication C-Reactive Protein Treatment Outcome biology.protein Biomarker (medicine) Drug Therapy Combination Female Self Report business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Psychoneuroendocrinology. 78 |
| ISSN: | 1873-3360 |
| Popis: | Currently, no valid measures inform treatment selection for depressed patients. Whether C-reactive protein (CRP) in particular and two other acute phase reactants (inflammatory markers) could differentiate between patients responding to either of two treatments with different mechanisms of action was assessed.Subjects included Combining Medications to Enhance Depression Outcomes (CO-MED) trial participants randomly assigned to either escitalopram plus placebo (SSRI monotherapy, n=51) or bupropion plus escitalopram combination (bupropion-SSRI combination, n=55) with baseline plasma samples. CRP, serum amyloid P component, and alpha-2-macroglobulin were measured using the Bioplex Pro™ human acute-phase 4-plex panel. We conducted mixed model analyses of depressive symptom (Quick Inventory of Depressive Symptomatology Self-Report) and side-effect burden (Frequency, Intensity, and Burden of Side-Effects Rating Scale) obtained weekly or every other week over the 12-week acute-phase of CO-MED trial to evaluate the relationship between these outcomes and baseline CRP and other acute-phase reactants.The treatment arms did not differ in depressive symptom or side effect outcomes. Most participants (69.8%, 74/106) had baseline CRP levels greater than 1mg/L (indicative of systemic inflammatory activity). Higher baseline CRP levels were associated lower depression severity (correlation coefficient=-0.63) with bupropion-SSRI combination but not with SSRI monotherapy (correlation coefficient=0.40). The overall remission rate was 41.5%. The estimated remission rate with CRP threshold based assignment (SSRI monotherapy for1mg/L and Bupropion-SSRI for ≥1mg/L) was 53.1%, with a number needed to treat of 8.6. Side effect burden was unrelated to any baseline inflammatory marker.Baseline CRP levels relate differentially to antidepressant treatment outcomes in persons with major depressive disorder. Clinicaltrials.gov identifier: NCT00590863. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect